GSK’s Shingrix was initially approved by the FDA in October 2017 for the prevention of shingles in adults aged 50 and older. However, the pandemic and CDC’s recommendation for individuals not to get another vaccine within weeks of receiving the COVID-19 vaccine has caused many people to miss vaccinations.

On Monday, the FDA approved Shingrix’s usage in adults aged 18 and older who are immunocompromised and are at a greater risk of developing shingles. It is now the first shingles vaccine approved for usage in adults who were immunodeficient or immunosuppressed due to disease or therapy, including patients with HIV, solid tumors, or renal transplants.

Click here to read the entire article.